apomorphine has been researched along with Parkinson Disease, Secondary in 184 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (13.59) | 18.7374 |
| 1990's | 84 (45.65) | 18.2507 |
| 2000's | 46 (25.00) | 29.6817 |
| 2010's | 28 (15.22) | 24.3611 |
| 2020's | 1 (0.54) | 2.80 |
| Authors | Studies |
|---|---|
| Ablat, N; Lei, H; Pu, X; Ren, R; Sun, Y; Zhang, K; Zhao, X | 1 |
| Funamizu, Y; Mizukami, H; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yagihashi, S | 1 |
| Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C | 1 |
| Ai, Y; Andersen, AH; Evans, A; Forman, E; Gash, DM; Grondin, R; Hardy, PA; Yue, G; Yue, J; Zhang, R; Zhang, Z | 1 |
| de Campos, PS; Hasegawa, K; Kawamura, LRSM; Kumei, Y; Zeredo, JL | 1 |
| Liu, J; Wang, X; Wang, Y | 1 |
| Haghdoost-Yazdi, H; Khandan-Chelarci, G; Sarukhani, MR | 1 |
| Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A | 1 |
| Chan, MH; Chang, PC; Chen, C; Chen, HH | 1 |
| Anderson, KA; Bhupal, PK; Dunbar, GL; Hoolsema, KS; Lynn, JD; Rossignol, J; Sandstrom, MI; Shall, GP | 1 |
| Chen, L; Cheng, L; Gao, C; Liu, H; Ren, Z; Wang, Y; Wei, X; Wen, H; Zeng, S; Zhang, X | 1 |
| Elliott, RB; Faull, RL; Geaney, MS; Law, L; Lee, JE; Lin, H; Luo, XM; Shaikh, SB; Skinner, SJ; Tan, PL; Waldvogel, H; Wang, W; Wynyard, S | 1 |
| Ba, YY; Guo, WW; Liu, HL; Wang, H; Wang, M; Wu, X; Yang, H; Zheng, L | 1 |
| Andersen, AH; Forman, E; Gash, DM; Gerhardt, GA; Grondin, RC; Hardy, PA; Zhang, Z | 1 |
| Avanzini, MA; Blandini, F; Bonizzi, A; Cerri, S; Fuzzati-Armentero, MT; Ghezzi, C; Greco, R; Levandis, G; Maccario, R; Mangione, AS | 1 |
| Butenko, GM; Kopjak, BS; Kyzminova, IA; Labunets, IF; Podjachenko, EV; Rodnichenko, AE; Sagach, VF; Talanov, SA; Utko, NA; Vasilyev, RG | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Aliaghaei, A; Gardaneh, M; Gharib, E; Maghsoudi, N; Salehinejad, P | 1 |
| Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Najafipour, R; Piri, H | 1 |
| Afshin-Majd, S; Baluchnejadmojarad, T; Bashiri, K; Kiasalari, Z; Roghani, M; Sedaghat, R | 1 |
| Bahri, MA; Becker, G; Garraux, G; Hustadt, F; Lemaire, C; Luxen, A; Michel, A; Plenevaux, A | 1 |
| Abuirmeileh, A; Harkavyi, A; Kingsbury, A; Lever, R; Whitton, PS | 1 |
| Ai, Y; Andersen, A; Ding, F; Forman, E; Gash, DM; Gerhardt, GA; Grondin, R; Hardy, P; Luan, L; Zhang, Z | 1 |
| Chen, Y; Ding, Z; Jiang, Y; Ren, H; Su, Y; Wang, J; Wu, J; Yu, W | 1 |
| Ali, U; Chen, L; Gui, ZH; Hui, YP; Li, Q; Liu, J; Wang, Y; Wu, ZH; Zhang, QJ | 1 |
| Amalric, M; Flor, PJ; Greco, B; Lopez, S; van der Putten, H | 1 |
| Fernandez-Espejo, E; Flores, JA; Gonzalez-Aparicio, R | 1 |
| Brantley, E; Karain, B; Shi, WX; Xu, D | 1 |
| Faraji, A; Fraidouni, N; Hadibeygi, E; Haghdoost-Yazdi, H; Movahedi, M; Vaezi, F | 1 |
| Cabrera, R; Casas, S; Escudero, C; García, S; Nanfaro, F; Yunes, R | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Heim, C; Kolasiewicz, W; Kurz, T; Schwegler, H; Sontag, KH; Sova, L | 1 |
| Baluchnejadmojarad, T; Behzadi, G; Roghani, M | 1 |
| Chung, JH; Joo, WS; Kim, CJ; Kim, YJ; Kim, YS; Lee, HJ; Lee, HS; Leem, K; Lim, S; Park, HJ; Seo, JC; Son, YS; Yin, CS | 1 |
| Cohen, AD; Schallert, T; Smith, AD; Tillerson, JL; Zigmond, MJ | 1 |
| Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I | 1 |
| Guo, LH; Hui, GZ; Reiser, J; Sun, B | 1 |
| Ceballos-Baumann, A | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Tanaka, H; Tomiyama, M | 1 |
| Bergman, H; Fainstein, N; Morris, G; Nevet, A; Saban, G | 1 |
| Brownell, AL; McNaught, KS; Olanow, CW; Perl, DP | 1 |
| Hashemi, L; Joghataie, MT; Negahdar, F; Roghani, M | 1 |
| McMillan, CR; Niles, LP; Sharma, R; Tenn, CC | 1 |
| Mewes, K; Russo, GS; Rye, DB; Vitek, JL; Zhang, J | 1 |
| Fu, AL; Jia, PY; Jin, GZ; Li, Q; Sun, MJ; Wang, YX; Wu, SP; Yu, LP | 1 |
| Aceves, J; Anaya-Martínez, V; Bannon, MJ; Flores, G; Garcia-Villegas, R; Gonzalez-Barrios, JA; Jiménez, I; Lindahl, M; Martinez-Arguelles, DB; Martinez-Fong, D; Navarro-Quiroga, I; Segovia, J; Trudeau, LE | 1 |
| Chen, SD; Liang, L; Lu, GQ; Wang, XJ; Xu, JY; Ye, M; Zhang, YH | 1 |
| Ji, XQ; Jin, DZ; Liu, DZ; Tang, CP; Ye, Y; Zhang, LM; Zhu, J; Zhu, XZ | 1 |
| Chen, XY; Li, J; Qi, WQ; Shen, SH | 1 |
| Kim, BK; Kim, CJ; Kim, SE; Kim, TS; Kim, YP; Ko, IG; Lee, HH; Shin, MS; Sung, YH; Yoon, MC | 1 |
| Abuirmeileh, A; Biggs, CS; Chowdrey, HS; Kingsbury, AE; Knight, RA; Lees, AJ; Lever, R; Locke, IC; Whitton, PS | 1 |
| Janowski, M; McGrogan, MP; Newcomb, JD; Sanberg, PR; Saporta, S; Willing, AE; Zigova, T | 1 |
| Kolb, B; Miklyaeva, EI; Whishaw, IQ | 1 |
| Chandra, G; Jayakrishnan, A; Mohanakumar, KP; Saravanan, KS; Senthilkumar, KS; Sindhu, KM | 1 |
| Balldin, J; Granérus, AK; Lindstedt, G; Modigh, K; Wålinder, J | 1 |
| Johnels, B; Steg, G | 1 |
| Kulkarni, SK; Verma, A | 1 |
| Akai, T; Kuno, S; Mizuta, E; Ozawa, M; Yamaguchi, M | 1 |
| Pontieri, FE; Porrino, LJ; Sokoloff, L; Viola, JJ | 1 |
| Boix, F; Fornaguera, J; Huston, JP; Schwarting, RK | 1 |
| Block, F; Clement, HW; Grote, C; Sontag, KH; Wesemann, W | 1 |
| Crossman, AR; Page, RD; Sambrook, MA | 1 |
| Bösch, MF; Ludin, HP | 1 |
| Bassetti, MA; Pasqualetti, P; Rossini, PM | 1 |
| Leiguarda, R; Merello, M; Migliorelli, R; Petracchi, M; Sabe, L; Starkstein, S; Teson, A | 1 |
| Mecír, P; Roth, J; Růzicka, E | 1 |
| During, MJ; Kaplitt, MG; Leone, P; O'Malley, KL; Pfaff, DW; Samulski, RJ; Xiao, X | 1 |
| Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Gash, DM; Sakai, K | 1 |
| Dahlström, A; McRae, A | 1 |
| Bankiewicz, KS; Cummins, A; Oldfield, EH; Palmatier, M; Plunkett, RJ | 1 |
| Fisher, LJ; Gage, FH; Shimohama, S | 1 |
| Herrero, MT; Laguna, J; Luquin, MR; Obeso, JA | 1 |
| Crossman, AR; Graham, WC; Sambrook, MA | 1 |
| Gurevich, V; Jiao, S; Wolff, JA | 1 |
| Kuno, S; Mizuta, E; Sasa, M; Yoshida, O; Yoshimura, N | 1 |
| Akai, T; Kuno, S; Mizuta, E; Yamaguchi, M | 1 |
| Albin, RL; Becker, JB; Curran, EJ | 1 |
| Fouillet, N; Henry, P; Tison, F | 1 |
| Björklund, A; Duan, WM; Jödicke, A; Knappe, U; Nikkhah, G | 1 |
| Yoshida, M | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Poewe, W; Wagner, M | 1 |
| Bohn, MC; Breakefield, XO; Collier, TJ; Frim, DM; Lin, Q; Yoshimoto, Y | 1 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Bringmann, G; God, R; Heim, C; Rausch, WD; Reichmann, H; Riederer, P; Sontag, KH; Sontag, TA; Wesemann, W | 1 |
| Baskin, P; Salamone, J | 1 |
| Cataneo, EA; Leiguarda, R; Manes, F; Merello, M; Petracca, G; Starkstein, S | 1 |
| Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Flumerfelt, BA; Newman, DD; Rajakumar, N; Stoessl, AJ | 1 |
| Heim, C; Sontag, KH | 1 |
| Labandeira García, JL; Rozas, G | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Heneka, MT; Klockgether, T; Kunow, M; Löschmann, PA; Schulz, JB; Wachtel, H; Wüllner, U | 1 |
| Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F | 1 |
| Kuno, S | 1 |
| Borlongan, CV; Cameron, DF; Sanberg, PR; Saporta, S | 1 |
| Guerra, MJ; Labandeira-García, JL; Rozas, G | 1 |
| Schroeder, SR; Stodgell, CJ; Tessel, RE; Van Keuren, KR | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Agid, Y; Dziewczapolski, G; García, MC; Gershanik, O; Menalled, LB; Murer, MG; Raisman-Vozari, R | 1 |
| Cohen, LK; Leff, SE; Mandel, RJ; Rendahl, KG; Snyder, RO; Spratt, SK | 1 |
| Borlongan, CV; Sanberg, PR; Saporta, S | 1 |
| Kang, UJ; Leff, SE; Mandel, RJ; Rendahl, KG; Spratt, SK | 1 |
| Alvarez, P; Blanco, L; Macías, R; Pavón, N; Rodríguez, A; Torres, A; Vidal, L | 1 |
| Annett, LE; Dunnett, SB; Henderson, JM; Torres, EM | 1 |
| Guerra, MJ; Labandeira-García, JL; López-Martín, E; Rozas, G | 1 |
| Alvarez-Fonseca, P; Blanco, L; Castellano, O; Castillo, L; García, A; Macías, R; Pavón, N; Rosillo, JC; Vidal, L | 1 |
| Cao, L; Chen, SD; Jiang, ZH; Liu, XY; Ni, ZM; Zhao, YC; Zheng, ZC; Zhou, CF | 1 |
| Benabid, AL; Benazzouz, A; Bressand, K; Gao, DM; Ilinsky, IA; Kultas-Ilinsky, K; Piallat, B | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Samii, M; Winkler, C | 1 |
| Harvey-White, J; Jacobowitz, DM; Kopin, IJ; Lamensdorf, I; Meiri, N | 1 |
| Albanese, A; Moro, E | 1 |
| Möller, JC; Oertel, WH; Pogarell, O | 1 |
| Chang, JW; Kang, UJ; Wachtel, SR; Young, D | 1 |
| Björklund, A; Devaux, B; Kirik, D; Moffat, B; Phillips, HS; Rosenblad, C | 1 |
| Hughes, AJ | 1 |
| Mandel, RJ | 1 |
| Davidson, BL; During, MJ; Freese, A; Janson, CG; Leone, P; McPhee, SW | 1 |
| Aebischer, P; Bensadoun, JC; Déglon, N; Ridet, JL; Tseng, JL; Zurn, AD | 1 |
| Andbjer, B; Fuxe, K; Kehr, J; Strömberg, I | 1 |
| Antkiewicz-Michaluk, L; Michaluk, J; Papla, I; Romańska, I; Vetulani, J | 1 |
| Koga, K; Kurokawa, M; Kuwana, Y; Nakamura, J; Ochi, M | 1 |
| Dabbeni-Sala, F; Franceschini, D; Giusti, P; Skaper, SD | 1 |
| Cui, X; Gao, J; Li, C; Li, X; Luo, Y; Sun, AM; Sun, R; Wang, L; Wang, Z; Xi, Z; Xue, Y; Zhou, D | 1 |
| Grünblatt, E; Mandel, S; Maor, G; Youdim, MB | 2 |
| Cohen, AD; Miller, GW; Philhower, J; Schallert, T; Tillerson, JL; Zigmond, MJ | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Armando, I; Belforte, JE; Buño, W; Magariños-Azcone, C; Pazo, JH | 1 |
| Chen, MT; Hoffer, BJ; Janak, PH; Morales, M; Woodward, DJ | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Boules, M; Fauq, A; McCormick, D; Richelson, E; Warrington, L | 1 |
| Shults, CW; Tsuboi, K | 1 |
| Cools, AR; van Oosten, RV | 1 |
| Brotchie, JM; Crossman, AR; Silverdale, MA | 1 |
| Kamel, D; Kay, TS; Krentz, L; Meshul, CK; Moore, C | 1 |
| Borison, RL; Diamond, BI | 1 |
| Finn, BW; Mendez, JS | 1 |
| Wolfarth, S | 1 |
| Poirier, LJ | 1 |
| Avakian, RM; Dutov, AA; Parkhomenko, VM | 1 |
| Kunow, M; Löschmann, PA; Wachtel, H | 2 |
| Quinn, NP; Steiger, MJ | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Matsuda, S; Nishiyama, N; Saito, H | 1 |
| Cadet, JL; Zhu, SM | 1 |
| Borrelli, E; Haby, C; Hindelang, C; Lisovoski, F; Revel, MO; Schleef, C; Zwiller, J | 1 |
| Chen, S | 1 |
| Beninger, RJ; Miller, R | 1 |
| Bédard, PJ; Filion, M; Tremblay, L | 2 |
| Ebner, TJ; Friehs, GM; Haines, SJ; He, LS; Parker, RG; Turner, DA | 1 |
| Bennett, JP; Orosz, D | 1 |
| Deutch, AY; During, MJ; Freese, A; Kibat, PG; Langer, R; Roth, RH; Sabel, BA | 1 |
| Abbott, RJ; D'Costa, DF; Millac, PA; Pye, IF | 1 |
| Burton, S; Daya, S; Potgieter, B | 1 |
| Hughes, AJ; Lees, AJ; Stern, GM | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Attanasio, A; Cannata, D; Capria, A; Leggiadro, G; Michisanti, M; Ruggieri, S; Stocchi, F | 1 |
| Dymecki, J; Freed, WJ | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 1 |
| Dunnett, SB; Morris, BJ; Northrop, AJ; Sirinathsinghji, DJ | 1 |
| Archer, T; Fredriksson, A; Sundström, E | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Luquin, R; Mitchell, IJ; Robertson, RG; Sambrook, MA | 1 |
| Aebischer, P; Tresco, PA; Wahlberg, L; Winn, SR | 1 |
| Bankiewicz, KS; Ewing, SE; Perese, DA; Ulman, J; Viola, J | 1 |
| Barker, R; Duncan, J; Lees, A | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Lees, A; Stern, G; Stibe, C | 1 |
| Carey, RJ | 1 |
| Burunat, E; Castro, R; Díaz-Palarea, MD; Rodríguez, M | 1 |
| Cadet, JL; de Yebenes, JG; Dwork, A; Fahn, S; Herbert, J; Jackson-Lewis, V; Pezzoli, G; Truong, DD | 1 |
| Bédard, PJ; Bouchard, S; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Beresford, IJ; Hall, MD; Heavens, RP; Richards, SJ; Sirinathsinghji, DJ | 1 |
| Bankiewicz, KS; Chiueh, CC; Doppman, JL; Jacobowitz, DM; Kopin, IJ; Oldfield, EH | 1 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
| Hornykiewicz, O | 1 |
| Albert, E | 1 |
| Cotzias, GC | 1 |
| Arnold, OH; Collard, J; Deniker, P; Ginestet, D; Hippius, H; Itil, TM; Labhardt, F; Leeds, AA; Montanini, R; Morozov, G; Simon, P; Villeneuve, A | 1 |
9 review(s) available for apomorphine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
Topics: Adult; Antiparkinson Agents; Apomorphine; Brain Damage, Chronic; Female; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
[The diagnosis of the parkinsonian syndrome].
Topics: Antiparkinson Agents; Apomorphine; Brain; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease, Secondary; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
Apomorphine test in the assessment of parkinsonian patients: a meta-analysis.
Topics: Apomorphine; Disease Progression; Dopamine Agonists; Humans; Parkinson Disease; Parkinson Disease, Secondary | 1999 |
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Brain; Carbachol; Caudate Nucleus; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Humans; Movement Disorders; Parasympathetic Nervous System; Parasympathomimetics; Parkinson Disease; Parkinson Disease, Secondary; Rabbits; Rats; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra; Synapses | 1976 |
On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Apomorphine; Benzazepines; Corpus Striatum; Dominance, Cerebral; Dopamine; Dopamine Agents; Dopamine Antagonists; Drug Interactions; Functional Laterality; Locomotion; Parkinson Disease, Secondary; Phenethylamines; Posture; Rats; Receptors, Dopamine; Reward; Stereotyped Behavior | 1991 |
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
Topics: Administration, Oral; Aged; Apomorphine; Drug Evaluation; False Negative Reactions; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease, Secondary; Probability | 1990 |
Dopamine and extrapyramidal motor function and dysfunction.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Butyrophenones; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Electric Stimulation; Extrapyramidal Tracts; Humans; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Phenylacetates; Reserpine; Substantia Nigra; Visual Cortex | 1972 |
[Therapy and problems of parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Antidepressive Agents; Apomorphine; Brain Chemistry; Brain Stem; Dihydroxyphenylalanine; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Stereotaxic Techniques; Sympathomimetics | 1971 |
3 trial(s) available for apomorphine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Cross-Over Studies; Double-Blind Method; Female; Humans; Levodopa; Motor Activity; Parkinson Disease, Secondary; Psychiatric Status Rating Scales; Schizophrenia | 1996 |
Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
Topics: Adult; Antiparkinson Agents; Apomorphine; Brain Damage, Chronic; Female; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations.
Topics: Adult; Aged; Apomorphine; Clinical Trials as Topic; Ergolines; Humans; Infusion Pumps; Lisuride; Middle Aged; Parkinson Disease, Secondary | 1987 |
173 other study(ies) available for apomorphine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Neuroprotective Effects of Safflower Flavonoid Extract in 6-Hydroxydopamine-Induced Model of Parkinson's Disease May Be Related to its Anti-Inflammatory Action.
Topics: Animals; Anti-Inflammatory Agents; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Brain; Carthamus tinctorius; Coculture Techniques; Dopamine; Flavonoids; Inflammasomes; Inflammation; Interleukin-1beta; Maze Learning; Mice; Neurons; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidopamine; Parkinson Disease, Secondary; Plant Extracts; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2020 |
Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Topics: Animals; Apomorphine; Dendritic Spines; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Neurons; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Statistics, Nonparametric; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Analysis of respiratory movements in a mouse model of late Parkinson's disease submitted to stress.
Topics: Animals; Apomorphine; Cineradiography; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Respiration; Stress, Physiological; Sympatholytics | 2018 |
Electroacupuncture Alleviates Motor Symptoms and Up-Regulates Vesicular Glutamatergic Transporter 1 Expression in the Subthalamic Nucleus in a Unilateral 6-Hydroxydopamine-Lesioned Hemi-Parkinsonian Rat Model.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dopamine Agonists; Electroacupuncture; Functional Laterality; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus; Tyrosine 3-Monooxygenase; Up-Regulation; Vesicular Glutamate Transport Protein 1 | 2018 |
Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.
Topics: Animals; Apomorphine; Biomarkers; Cell Death; Dopamine; Dopamine Agonists; Male; Neurons; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Predictive Value of Tests; Rats; Rats, Wistar; Substantia Nigra; Tyrosine 3-Monooxygenase; Uric Acid | 2018 |
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorders; Mice; Mice, Inbred ICR; Motor Activity; Oxidopamine; Oxonic Acid; Parkinson Disease, Secondary; Rotarod Performance Test; Tyrosine 3-Monooxygenase; Uric Acid | 2019 |
Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
Topics: Animals; Apomorphine; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Lignans; Male; Mice; Microinjections; Motor Activity; Neuroprotective Agents; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Substantia Nigra; Tyrosine 3-Monooxygenase | 2018 |
Behavioral and neurochemical responses derived from dopaminergic intrastriatal grafts in hemiparkinsonian rats engaged in a novel motor task.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Cell Differentiation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Functional Laterality; LIM-Homeodomain Proteins; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Microdialysis; Oxidopamine; Parkinson Disease, Secondary; Phosphopyruvate Hydratase; Rats; Rats, Sprague-Dawley; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2018 |
NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
Topics: Acetophenones; Animals; Apomorphine; Cell Line, Transformed; Corpus Striatum; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Gene Expression Regulation; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidase 2; Nerve Degeneration; Nod2 Signaling Adaptor Protein; Oxidopamine; Parkinson Disease, Secondary; Reactive Oxygen Species | 2018 |
Recovery of neurological functions in non-human primate model of Parkinson's disease by transplantation of encapsulated neonatal porcine choroid plexus cells.
Topics: Animals; Animals, Newborn; Apomorphine; Cell Transplantation; Choroid Plexus; Dopamine Agonists; Immunohistochemistry; Macaca mulatta; Male; Movement; MPTP Poisoning; Neostriatum; Nerve Net; Neurologic Examination; Parkinson Disease, Secondary; Posture; Recovery of Function; Rotation; Swine; Tyrosine 3-Monooxygenase | 2013 |
[Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Topics: Administration, Oral; Alkaloids; Animals; Apomorphine; Catalase; Dopamine Agonists; Dopaminergic Neurons; Glutathione; Glutathione Peroxidase; Male; Malondialdehyde; Motor Activity; Neostriatum; Nitric Oxide; Nitric Oxide Synthase; Oxidopamine; Parkinson Disease, Secondary; Piper; Random Allocation; Rats; Rats, Sprague-Dawley; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2014 |
Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Apomorphine; Basal Ganglia; Benzazepines; Diagnosis, Differential; Dopamine Agents; Female; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Parkinson Disease, Secondary; Raclopride | 2015 |
Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
Topics: Animals; Apomorphine; Behavior, Animal; Blood-Brain Barrier; Carotid Arteries; Cell Count; Cell Tracking; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Injections, Intra-Arterial; Injections, Intraventricular; Male; Mannitol; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Neurons; Osmolar Concentration; Oxidopamine; Parkinson Disease, Secondary; Permeability; Rats; Rats, Wistar | 2015 |
[THYMIC HORMONES, ANTIOXIDANT ENZYMES AND NEUROGENESIS OF BULBUS OLFACTORIUS IN RATS WITH PARKINSONISM: THE EFFECT OF MELATONIN].
Topics: Animals; Antioxidants; Apomorphine; Ataxia; Catalase; Cell Count; Cell Differentiation; Dopamine Agonists; Gene Expression; Glutathione Peroxidase; Male; Melatonin; Nestin; Neural Stem Cells; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Superoxide Dismutase; Thymic Factor, Circulating; Thymus Gland | 2015 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Dopaminergic Induction of Umbilical Cord Mesenchymal Stem Cells by Conditioned Medium of Choroid Plexus Epithelial Cells Reduces Apomorphine-Induced Rotation in Parkinsonian Rats.
Topics: Animals; Apomorphine; Cell Differentiation; Cells, Cultured; Choroid Plexus; Culture Media, Conditioned; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Epithelial Cells; Humans; Mesenchymal Stem Cells; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Umbilical Cord | 2016 |
Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
Topics: 4-Aminopyridine; Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Synergism; Male; Malondialdehyde; Medial Forebrain Bundle; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Potassium Channel Blockers; Rats; Rotarod Performance Test; Tetraethylammonium | 2017 |
Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Topics: Acetylcarnitine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; Inflammation; Male; Neural Pathways; Nootropic Agents; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 2017 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radioisotopes; Image Processing, Computer-Assisted; Male; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Presynaptic; Stereotyped Behavior; Tyrosine | 2017 |
The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Hydroxydopamines; Lipopolysaccharides; Male; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Wistar; Recovery of Function; Time Factors; Tyrosine 3-Monooxygenase; Urocortins | 2008 |
Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Macaca mulatta; Magnetic Resonance Imaging; Neurotoxins; Parkinson Disease, Secondary | 2008 |
Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.
Topics: Acetylcysteine; Animals; Antimetabolites; Apomorphine; Behavior, Animal; Blotting, Western; Bone Marrow Transplantation; Bromodeoxyuridine; Cysteine Proteinase Inhibitors; Dopamine; Dopamine Agonists; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Neostriatum; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Tissue Engineering; Tyrosine 3-Monooxygenase | 2010 |
Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease.
Topics: Action Potentials; Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Locus Coeruleus; Male; Movement; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Apomorphine; Benzhydryl Compounds; Catalepsy; Disease Models, Animal; Haloperidol; Male; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Reaction Time; Receptors, Metabotropic Glutamate; Stereotyped Behavior | 2010 |
Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats.
Topics: Algorithms; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Blotting, Western; Central Nervous System Stimulants; Dopamine Agonists; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Immunohistochemistry; Infusion Pumps, Implantable; Male; Microinjections; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Sympatholytics; Transforming Growth Factor beta1 | 2010 |
Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Electrophysiological Phenomena; Evoked Potentials; GABA Agonists; Levodopa; Male; Muscimol; Neurons; Parkinson Disease, Secondary; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Substantia Nigra | 2011 |
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions; Male; Medial Forebrain Bundle; Microinjections; Oxidopamine; Parkinson Disease, Secondary; Potassium Channel Blockers; Rats; Rats, Wistar; Tetraethylammonium | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; Memory; Oxidopamine; Parkinson Disease, Secondary; Progesterone; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Stereotyped Behavior; Swimming; Sympatholytics | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology?
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agonists; Male; Maze Learning; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Red Nucleus; Substantia Nigra; Swimming; Tegmentum Mesencephali | 2002 |
Efficacy of elevated body swing test in the early model of Parkinson's disease in rat.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Substantia Nigra; Sympatholytics | 2002 |
Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
Topics: Acupuncture Therapy; Animals; Apomorphine; Behavior, Animal; Cell Count; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Immunohistochemistry; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, trkB; Substantia Nigra; Tyrosine 3-Monooxygenase | 2003 |
Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Casts, Surgical; Corpus Striatum; Disease Models, Animal; Dopamine; Forelimb; Functional Laterality; Glial Cell Line-Derived Neurotrophic Factor; Immobilization; Male; Medial Forebrain Bundle; Motor Activity; Nerve Growth Factors; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rats, Sprague-Dawley | 2003 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission | 2003 |
Dopaminergic trophism after intrastriatal injection of lentivirus-transferred GDNF in Parkinson rat model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Line; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Humans; Immunohistochemistry; Lentivirus; Male; Nerve Growth Factors; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |
Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Topics: Animals; Apomorphine; Autoradiography; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Receptor, Adenosine A2A; RNA, Messenger; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics; Up-Regulation | 2004 |
Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Electrophysiology; Female; Globus Pallidus; Macaca; Neurons; Parkinson Disease, Secondary; Substantia Nigra | 2004 |
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain; Carbon Radioisotopes; Cocaine; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dopamine Uptake Inhibitors; Hazardous Substances; Humans; Inclusion Bodies; Male; Molecular Structure; Multienzyme Complexes; Oligopeptides; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Rats; Rats, Sprague-Dawley; Tomography, Emission-Computed | 2004 |
Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Caffeine; Cell Count; Central Nervous System Stimulants; Functional Laterality; Male; Nerve Degeneration; Neurons; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotation; Stereotyped Behavior; Substantia Nigra | 2004 |
Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain-Derived Neurotrophic Factor; Densitometry; Dopamine Agonists; Functional Laterality; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Male; Melatonin; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Melatonin, MT1; Receptors, Melatonin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stereotyped Behavior; Sympatholytics; Tyrosine 3-Monooxygenase | 2006 |
Lesions in monkey globus pallidus externus exacerbate parkinsonian symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Catheter Ablation; Disease Models, Animal; Dopamine Agonists; Globus Pallidus; Macaca mulatta; Movement; Neurons; Parkinson Disease, Secondary | 2006 |
A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase.
Topics: Animals; Apomorphine; Blood-Brain Barrier; Brain Chemistry; Cell Line, Tumor; Gene Products, tat; Humans; Male; Oxidopamine; Parkinson Disease, Secondary; Peptide Fragments; Protein Structure, Tertiary; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Rotation; Stereotyped Behavior; tat Gene Products, Human Immunodeficiency Virus; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2006 |
Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats.
Topics: Animals; Apomorphine; Corpus Striatum; Dopamine; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Humans; Immunohistochemistry; Methamphetamine; Nanoparticles; Neurons; Neurotensin; Oxidopamine; Parkinson Disease, Secondary; Rats; Substantia Nigra; Time Factors; Transfection | 2006 |
Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Bone Marrow Transplantation; Cells, Cultured; Disease Models, Animal; Dopamine; Female; Glial Fibrillary Acidic Protein; Green Fluorescent Proteins; Humans; In Situ Hybridization; Motor Activity; Neurturin; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stromal Cells; Transfection; Tyrosine 3-Monooxygenase | 2007 |
Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Benzoates; Binding, Competitive; Bridged-Ring Compounds; Dopamine Agonists; Dopamine Antagonists; Glucosides; Hydroxydopamines; In Vitro Techniques; Male; Membranes; Microinjections; Monoterpenes; Neostriatum; Parkinson Disease, Secondary; Raclopride; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 2007 |
Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Stereotypic Movement Disorder; Substantia Nigra; Up-Regulation | 2007 |
Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Topics: Animals; Apomorphine; Cell Survival; Dopamine; Dopamine Agonists; Immunohistochemistry; Male; Neostriatum; Nerve Fibers; Neurons; Oxidopamine; Parkinson Disease, Secondary; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2007 |
The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
Topics: Animals; Apomorphine; Blotting, Western; Corticotropin-Releasing Hormone; Data Interpretation, Statistical; Dopamine; Lipopolysaccharides; Male; Neostriatum; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase; Urocortins | 2007 |
A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Line; Cell Transplantation; Dopamine; Dopamine Agonists; Graft Survival; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Stereotyped Behavior; Sympatholytics; Tyrosine 3-Monooxygenase | 2007 |
A golgi analysis of cortical pyramidal cells in the unilateral parkinson rat: absence of change in the affected hemisphere vs hypertrophy in the intact hemisphere.
Topics: Animals; Apomorphine; Cerebral Cortex; Dendrites; Dendritic Spines; Dextroamphetamine; Female; Forelimb; Golgi Apparatus; Hypertrophy; Motor Activity; Motor Cortex; Oxidopamine; Parkinson Disease, Secondary; Psychomotor Performance; Pyramidal Cells; Rats; Rats, Long-Evans; Rotation; Synapses | 2007 |
Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
Topics: Absorbable Implants; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Delivery Systems; Drug Interactions; Functional Laterality; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
Neuroendocrine evidence for increased responsiveness of dopamine receptors in humans following electroconvulsive therapy.
Topics: Adult; Aged; Apomorphine; Clonidine; Depressive Disorder; Electroconvulsive Therapy; Female; Growth Hormone; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Prolactin; Receptors, Dopamine; Reserpine | 1982 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Contraction; Muscle Rigidity; Muscle Tonus; Neurophysiology; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Reflex, Stretch; Reserpine | 1982 |
N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Catalepsy; Dizocilpine Maleate; Haloperidol; Ketamine; Mice; Neuroprotective Agents; Parkinson Disease, Secondary; Perphenazine; Rats; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior | 1995 |
Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride; Time Factors | 1995 |
Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Autoradiography; Corpus Striatum; Female; Glucose; Macaca mulatta; Male; Parkinson Disease, Secondary; Receptors, Dopamine | 1995 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Locomotion; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Serotonin; Substantia Nigra | 1993 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Monoamines; Dopamine; Dopamine Agents; Dopamine Antagonists; Hydroxyindoleacetic Acid; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Tryptophan | 1993 |
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
Topics: Afferent Pathways; Animals; Apomorphine; Axonal Transport; Brain Mapping; Chorea; Dyskinesia, Drug-Induced; Dystonia; Globus Pallidus; Horseradish Peroxidase; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus; Wheat Germ Agglutinins | 1993 |
[Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary | 1994 |
Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Electroencephalography; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Male; Median Nerve; Middle Aged; Parietal Lobe; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time | 1995 |
Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates.
Topics: Aged; Alzheimer Disease; Apomorphine; Case-Control Studies; Dementia; Depressive Disorder; Extrapyramidal Tracts; Female; Humans; Interview, Psychological; Male; Neuropsychological Tests; Parkinson Disease, Secondary; Prevalence; Severity of Illness Index | 1994 |
[The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.
Topics: Adenoviruses, Human; Animals; Apomorphine; Behavior, Animal; beta-Galactosidase; Brain; Corpus Striatum; Cytomegalovirus; Dependovirus; Gene Expression Regulation, Viral; Genes, Reporter; Genes, Synthetic; Genetic Therapy; Genetic Vectors; Helper Viruses; Humans; Male; Microinjections; Oxidopamine; Parkinson Disease, Secondary; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Simian virus 40; Substantia Nigra; Transfection; Tyrosine 3-Monooxygenase | 1994 |
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Movement; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity; Nerve Fibers; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA induced parkinsonism.
Topics: Animals; Apomorphine; Capsules; Dopamine; Immunohistochemistry; Lactic Acid; Male; Microspheres; Neostriatum; Nerve Endings; Nerve Fibers; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1994 |
Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amnion; Animals; Apomorphine; Caudate Nucleus; Cerebral Ventricles; Dopamine; Dopamine beta-Hydroxylase; Fetal Tissue Transplantation; Graft Survival; Macaca mulatta; Motor Activity; Nerve Fibers; Nerve Regeneration; Nucleus Accumbens; Parkinson Disease, Secondary; Putamen; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Intracerebral grafting of genetically modified cells. Applications to a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Corpus Striatum; Fibroblasts; Genetic Engineering; Oxidopamine; Parkinson Disease, Secondary; Rats; Stereotyped Behavior; Transfection; Tyrosine 3-Monooxygenase | 1993 |
Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Drug Tolerance; Female; Macaca fascicularis; Male; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Psychomotor Performance | 1993 |
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Caudate Nucleus; Dopamine Agents; Female; Infusions, Intravenous; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1993 |
Long-term correction of rat model of Parkinson's disease by gene therapy.
Topics: Animals; Animals, Newborn; Apomorphine; Brain; Cells, Cultured; Dopamine; Drug Carriers; Female; Genetic Therapy; Levodopa; Motor Activity; Muscles; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylethanolamines; Plasmids; Rats; Rats, Sprague-Dawley; Time Factors; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 1993 |
The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dopamine Agents; Ergolines; Macaca fascicularis; Male; Parkinson Disease, Secondary; Quinpirole; Reflex; Urinary Bladder; Urination | 1993 |
Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Topics: Aggression; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Haloperidol; Lisuride; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine D2; Time Factors | 1993 |
Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Benzazepines; Cerebral Ventricles; Corpus Striatum; Denervation; Female; Functional Laterality; In Situ Hybridization; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptors, Dopamine D2; RNA, Messenger; Rotation; Spiperone; Substantia Nigra; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 1993 |
Apomorphine increases blood glucose concentrations in Parkinson's disease.
Topics: Aged; Apomorphine; Blood Glucose; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Caudate Nucleus; Corpus Striatum; Denervation; Dextroamphetamine; Dopamine; Ergolines; Feeding Behavior; Female; Fetal Tissue Transplantation; Forelimb; Motor Activity; Orientation; Oxidopamine; Parkinson Disease, Secondary; Putamen; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Regression Analysis; Rotation; Substantia Nigra | 1993 |
The neuronal mechanism underlying parkinsonism and dyskinesia, and differential roles of the putamen and caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Bicuculline; Cats; Caudate Nucleus; Globus Pallidus; Injections, Subcutaneous; Macaca; Motor Skills; Movement Disorders; Neural Pathways; Neurons; Parkinson Disease, Secondary; Picrotoxin; Putamen; Rats; Rats, Wistar; Synaptic Transmission | 1993 |
[Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Astrocytes; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Genetic Vectors; Humans; Male; Nerve Fibers; Nerve Growth Factors; Nerve Tissue Proteins; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Retroviridae; Rotation; Transduction, Genetic | 1995 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats.
Topics: Analysis of Variance; Animals; Apomorphine; Carbolines; Drug Administration Schedule; Female; Motor Activity; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Wistar; Time Factors | 1995 |
Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor.
Topics: Animals; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Jaw; Male; Muscarinic Antagonists; Neostriatum; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Scopolamine; Stereotyped Behavior; Tremor | 1996 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Agonists; Female; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Riluzole; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Thiazoles | 1996 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Injections; Injections, Intraventricular; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior; Substantia Nigra | 1995 |
A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease.
Topics: Animals; Apomorphine; Functional Laterality; Hippocampus; Infusions, Parenteral; Levodopa; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation | 1997 |
The halogenated tetrahydro-beta-carboline "TaClo": a progressively-acting neurotoxin.
Topics: Acclimatization; Animals; Apomorphine; Carbolines; Circadian Rhythm; Drug Synergism; Motor Activity; Neurotoxins; Parkinson Disease, Secondary; Rats; Time Factors | 1997 |
Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test.
Topics: Amphetamine; Animals; Apomorphine; Automation; Brain Tissue Transplantation; Female; Fetal Tissue Transplantation; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Reference Values; Rotation; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 1997 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agonists; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior | 1997 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; Movement Disorders; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Papio; Parkinson Disease, Secondary; Propionates; Putamen; Riluzole; Thiazoles | 1997 |
Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Dopamine Agonists; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1997 |
Intracerebral transplantation of testis-derived sertoli cells promotes functional recovery in female rats with 6-hydroxydopamine-induced hemiparkinsonism.
Topics: Animals; Apomorphine; Corpus Striatum; Dominance, Cerebral; Female; Graft Enhancement, Immunologic; Locomotion; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sertoli Cells; Sex Characteristics; Substantia Nigra; Transplantation, Heterotopic | 1997 |
An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism.
Topics: Animals; Apomorphine; Automation; Brain; Disease Models, Animal; Equipment Design; Female; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reference Values; Reproducibility of Results | 1997 |
Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
Topics: Amphetamine; Animals; Apomorphine; Conditioning, Operant; Corpus Striatum; Discrimination Learning; Disease Models, Animal; Dopamine; Dopamine Agents; Male; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reinforcement Schedule | 1998 |
Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Agonists; Electrochemistry; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Fibers; Nerve Tissue Proteins; Neuropeptides; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1998 |
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; GTP Cyclohydrolase; Humans; Levodopa; Male; Microdialysis; Neurons; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Proteins; Rotation; Tyrosine 3-Monooxygenase | 1998 |
Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promote long-term functional recovery in hemiparkinsonian rats.
Topics: Adrenal Glands; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Astrocytes; Behavior, Animal; Cell Transplantation; Chromaffin Cells; Chromogranin A; Chromogranins; Complement C3b; Corpus Striatum; Glial Fibrillary Acidic Protein; Male; Microglia; Microspheres; Motor Activity; Nerve Fibers; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Serotonin; Sympatholytics; Tyrosine 3-Monooxygenase | 1998 |
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
Topics: 3T3 Cells; Animals; Antioxidants; Antiparkinson Agents; Apomorphine; Behavior, Animal; Biopterins; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Fibroblasts; Gene Expression Regulation, Enzymologic; Genetic Therapy; Gliosarcoma; GTP Cyclohydrolase; Humans; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Fusion Proteins; Retroviridae; Transformation, Genetic; Transgenes; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1998 |
[Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dextroamphetamine; Dominance, Cerebral; Dopamine; Dose-Response Relationship, Drug; Feeding Behavior; Foot; Forelimb; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Psychomotor Performance; Rats; Rats, Wistar; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical; Sympatholytics | 1998 |
Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus).
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Dopamine Uptake Inhibitors; Female; Head Movements; Male; Motor Activity; Parkinson Disease, Secondary; Rotation; Thalamic Nuclei | 1998 |
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1998 |
[Simultaneous transplantation of fetal mesencephalic cells to the striatum and globus pallidus of rats with lesions induced by 6-hydroxydopamine].
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Fetal Tissue Transplantation; Globus Pallidus; Male; Mesencephalon; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar | 1998 |
[Expression of foreign tyrosine hydroxylase gene in the rat model of Parkinson's disease].
Topics: Animals; Apomorphine; Gene Expression; Genetic Therapy; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Transfection; Tyrosine 3-Monooxygenase | 1997 |
High-frequency stimulation of the subthalamic nucleus suppresses experimental resting tremor in the monkey.
Topics: Animals; Apomorphine; Brain Stem; Cerebral Ventriculography; Electric Stimulation Therapy; Electrocoagulation; Functional Laterality; Macaca fascicularis; Male; Parkinson Disease, Secondary; Red Nucleus; Substantia Nigra; Thalamic Nuclei; Thalamus; Tremor | 1999 |
Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Cell Count; Dopamine; Dopamine Agonists; Female; Fetal Tissue Transplantation; Forelimb; gamma-Aminobutyric Acid; Immunohistochemistry; In Situ Hybridization; Mesencephalon; Motor Activity; Movement; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1999 |
Kir6.2 oligoantisense administered into the globus pallidus reduces apomorphine-induced turning in 6-OHDA hemiparkinsonian rats.
Topics: Animals; Apomorphine; Globus Pallidus; Male; Motor Activity; Neurons; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinson Disease, Secondary; Peptide Fragments; Rats; Rats, Sprague-Dawley; Rotation | 1999 |
Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions.
Topics: Adaptation, Physiological; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Female; Forelimb; Gait; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 1999 |
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Atrophy; Body Weight; Cerebral Ventricles; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; ELAV Proteins; Female; Glial Cell Line-Derived Neurotrophic Factor; Hydrogen-Ion Concentration; Injections, Intraventricular; Nerve Degeneration; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Neurturin; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 1999 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rotation; Substantia Nigra; Sympatholytics | 2000 |
Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats.
Topics: Adenoviridae; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Phenotype; Rats; Rats, Inbred F344; Recovery of Function; Treatment Outcome; Tyrosine 3-Monooxygenase | 2000 |
Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Dopamine; Genes, Reporter; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Lentivirus; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Microinjections; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 2000 |
Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
Topics: Animals; Apomorphine; Benzazepines; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Fetal Tissue Transplantation; Glutamic Acid; Membrane Potentials; Mesencephalon; Microdialysis; Microelectrodes; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic Acid; Isoquinolines; Male; Motor Activity; Neurotoxins; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tetrahydroisoquinolines; Tritium | 2000 |
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Xanthines | 2000 |
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron Transport Complex IV; Electrophoresis, Polyacrylamide Gel; Male; Melatonin; Mitochondria; Motor Activity; NAD; Neuroprotective Agents; Oxidative Phosphorylation; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |
Microencapsulated bovine chromaffin cell xenografts into hemiparkinsonian rats: a drug-induced rotational behavior and histological changes analysis.
Topics: Animals; Apomorphine; Capsules; Cattle; Cell Survival; Chromaffin Cells; Disease Models, Animal; Female; Microscopy, Fluorescence; Parkinson Disease; Parkinson Disease, Secondary; Psychomotor Disorders; Rats; Rats, Sprague-Dawley; Rotation; Sensitivity and Specificity; Transplantation, Heterologous | 2001 |
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Binding, Competitive; Catecholamines; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Glutathione; Glutathione Disulfide; Immunohistochemistry; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Stereoisomerism; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Surgical; Corpus Striatum; Disease Models, Animal; Dopamine; Forelimb; Homovanillic Acid; Immobilization; Male; Medial Forebrain Bundle; Membrane Glycoproteins; Membrane Transport Proteins; Microinjections; Neural Pathways; Neurons; Neuropeptides; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Substantia Nigra; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2001 |
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; DNA, Complementary; Dopamine Agents; Gene Expression; In Situ Hybridization; Male; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Parkinson Disease, Secondary; Reverse Transcriptase Polymerase Chain Reaction | 2001 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Calcium Channel Blockers; Calcium Channels, L-Type; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Flunarizine; Haloperidol; Male; Microinjections; Neostriatum; Nifedipine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synapses; Synaptic Transmission | 2001 |
In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
Topics: Action Potentials; Anesthesia; Animals; Apomorphine; Chloral Hydrate; Corpus Striatum; Disease Models, Animal; Dopamine; Electrodes, Implanted; Male; Microelectrodes; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Receptors, Dopamine D2; Wakefulness | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Motor Activity; Neurotensin; Oxidopamine; Parkinson Disease, Secondary; Peptide Fragments; Rats; Rats, Sprague-Dawley | 2001 |
Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glial Cell Line-Derived Neurotrophic Factor; Hedgehog Proteins; Humans; Microinjections; Motor Activity; Myristic Acid; Nerve Growth Factors; Nerve Tissue Proteins; Organ Specificity; Oxidopamine; Parkinson Disease, Secondary; Peptide Fragments; Rats; Trans-Activators; Tyrosine 3-Monooxygenase | 2002 |
Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty.
Topics: Animals; Apomorphine; Behavior, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Male; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Spatial Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Female; Ligands; Macaca mulatta; Male; Organ Specificity; Parkinson Disease, Secondary; Pyrimidines; Radioligand Assay; Receptors, AMPA | 2002 |
Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Drug Administration Schedule; Drug Antagonism; Extracellular Space; Glutamic Acid; Immunohistochemistry; Male; Microdialysis; Microscopy, Electron; Motor Activity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Synapses | 2002 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Levodopa; Male; Movement; Nerve Degeneration; Neurons; Neurotransmitter Agents; Oxotremorine; Parkinson Disease, Secondary; Rats; Rotation; Stereotaxic Techniques; Substantia Nigra; Synaptic Transmission; Time Factors | 1975 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; Levodopa; Parkinson Disease, Secondary; Piribedil; Rats; Reserpine; Tyrosine | 1975 |
[Preconvulsive state and hyperfunction of the striatum (clinico-experimental findings)].
Topics: Adolescent; Adult; Aged; Animals; Apomorphine; Convulsants; Corpus Striatum; Electroencephalography; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Pentylenetetrazole; Rats; Seizures | 1976 |
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamine Agents; Drug Synergism; Ibotenic Acid; Lisuride; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical | 1992 |
Levodopa challenge test in Parkinson's disease.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
Basic fibroblast growth factor ameliorates rotational behavior of substantia nigral-transplanted rats with lesions of the dopaminergic nigrostriatal neurons.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Fibroblast Growth Factor 2; Gliosis; Immunohistochemistry; Neural Pathways; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Rotation; Substantia Nigra | 1992 |
The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Biomarkers; Corpus Striatum; Immunohistochemistry; Injections; Male; Mazindol; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra; Synapses | 1992 |
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Drug Synergism; Lisuride; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Stereotaxic Techniques; Substantia Nigra | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Neurons, Efferent; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; RNA, Messenger; Spiperone; Stereotyped Behavior; Substantia Nigra | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Basal Ganglia; Dopamine Agents; Electrophysiology; Globus Pallidus; Macaca fascicularis; Motor Activity; Neurons; Parkinson Disease, Secondary; Phenethylamines | 1991 |
Lesioning of the striatum reverses motor asymmetry in the 6-hydroxydopamine rodent model of parkinsonism.
Topics: Adrenal Medulla; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Graft Survival; Immunohistochemistry; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Rotation; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical; Tyrosine 3-Monooxygenase | 1991 |
Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease.
Topics: Animals; Apomorphine; Dialysis; Disease Models, Animal; Dopamine; Ganglia, Sympathetic; Hydroxydopamines; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1990 |
Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes.
Topics: Animals; Apomorphine; Corpus Striatum; Delayed-Action Preparations; Dopamine; Drug Carriers; Hydroxydopamines; Liposomes; Male; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra | 1992 |
The apomorphine test in parkinsonian syndromes.
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Muscular Atrophy; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Prognosis; Supranuclear Palsy, Progressive | 1991 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Huntington Disease; Hydroxydopamines; Male; Melatonin; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinolinic Acid; Quinolinic Acids; Rats; Rats, Inbred Strains | 1991 |
Apomorphine test in parkinsonian syndromes.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease, Secondary | 1990 |
Transient cardiac arrest during continuous intravenous infusion of apomorphine.
Topics: Adult; Apomorphine; Electrocardiography; Heart Arrest; Humans; Infusions, Intravenous; Male; Monitoring, Physiologic; Parkinson Disease, Secondary; Time Factors | 1990 |
Effects of transplantation of cross-species substantia nigra into the lateral ventricle of rats with experimentally induced hemiparkinsonism.
Topics: Animals; Apomorphine; Cerebral Ventricles; Graft Survival; Hydroxydopamines; Motor Activity; Nerve Regeneration; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Substantia Nigra; Transplantation, Heterologous | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Autoradiography; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Female; Fetal Tissue Transplantation; Immunohistochemistry; Injections; Methamphetamine; Neural Pathways; Parkinson Disease, Secondary; Pregnancy; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1990 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Disease Models, Animal; Dopamine; Hydrazines; Levodopa; Male; Methyltyrosines; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1990 |
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia.
Topics: Animals; Apomorphine; Deoxy Sugars; Deoxyglucose; Dystonia; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary | 1990 |
An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats.
Topics: Acrylic Resins; Animals; Apomorphine; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Implants; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Polyvinyls; Rats; Rats, Inbred Strains | 1989 |
A 6-hydroxydopamine-induced selective parkinsonian rat model.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Disease Models, Animal; Functional Laterality; Hydroxydopamines; Limbic System; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Stereotyped Behavior | 1989 |
Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes.
Topics: Apomorphine; Diagnosis, Differential; Drug Administration Schedule; Humans; Injections, Subcutaneous; Parkinson Disease, Secondary; Pilot Projects | 1989 |
Apomorphine test for dopaminergic responsiveness.
Topics: Apomorphine; Diagnosis, Differential; Double-Blind Method; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism.
Topics: Action Potentials; Animals; Apomorphine; Corpus Striatum; Electric Stimulation; Globus Pallidus; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary | 1989 |
A conditioned anti-parkinsonian drug effect in the hemi-parkinsonian rat.
Topics: Animals; Apomorphine; Conditioning, Classical; Corpus Striatum; Dopamine; Hydroxydopamines; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains | 1986 |
Conditioning of the early behavioral response to apomorphine in the rotational model of Parkinson's disease.
Topics: Animals; Apomorphine; Conditioning, Psychological; Disease Models, Animal; Hydroxydopamines; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains | 1988 |
Non-chromaffin tissue plus nerve growth factor reduces experimental parkinsonism in aged rats.
Topics: Adrenal Medulla; Age Factors; Animals; Apomorphine; Hydroxydopamines; Injections, Intraventricular; Male; Nerve Growth Factors; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra; Time Factors | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Benzazepines; Brain Chemistry; Dopamine; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone | 1988 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--I. Behavioural, neurochemical and histological characterization of the lesion.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Female; Functional Laterality; Methamphetamine; Parkinson Disease, Secondary; Posture; Pyridinium Compounds; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1988 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Carotid Artery, Internal; Disease Models, Animal; Dominance, Cerebral; Dopamine; Homovanillic Acid; Injections, Intra-Arterial; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Pyridines | 1986 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |
Levodopa in the treatment of Parkinsonism.
Topics: Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dihydroxyphenylalanine; Dopamine; Esters; Humans; Hydrazines; Manganese Poisoning; Methylation; Methyldopa; Mice; Movement; Parkinson Disease; Parkinson Disease, Secondary; Phenylacetates | 1971 |
Definition and classification of neuroleptics.
Topics: Amphetamine; Animals; Apomorphine; Autonomic Nervous System; Basal Ganglia Diseases; Behavior; Catalepsy; Chemical Phenomena; Chemistry; Humans; Hypnotics and Sedatives; Motor Activity; Parkinson Disease, Secondary; Psychotic Disorders; Structure-Activity Relationship; Tranquilizing Agents | 1970 |